Literature DB >> 10223721

Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery.

M K Mansoura1, J Biwersi, M A Ashlock, A S Verkman.   

Abstract

Cl(-)-sensitive fluorescent indicators have been used extensively in cell culture systems to measure the Cl(-)-transporting function of the cystic fibrosis transmembrane conductance regulator protein CFTR. These indicators have been used in establishing a surrogate end point to assess the efficacy of CFTR cDNA delivery in human gene therapy trials. The ability to measure Cl- transport with high sensitivity in small and heterogeneous tissue samples makes the use of Cl- indicators potentially attractive in gene delivery studies. In this review article, the important technical aspects of Cl- transport measurements by fluorescent indicators such as SPQ are described, applications of Cl- indicators to assay CFTR function are critically evaluated, and new methodological developments are discussed. The available Cl- indicators have been effective in quantifying Cl- transport rates in cell culture models and in vitro systems such as isolated membrane vesicles and liposomes. However, the imperfect photophysical properties of existing Cl- indicators limit their utility in performing measurements in airway tissues, where gene transfer vectors are delivered in CF gene therapy trials. The low efficiency of gene transfer and the cellular heterogeneity in airway samples pose substantial obstacles to functional measurements of CFTR expression. Significant new developments in generating long-wavelength and dual-wavelength halide indicators are described, and recommendations are proposed for the use of the indicators in gene therapy trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223721     DOI: 10.1089/10430349950018274

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

Review 1.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

2.  Rescue of nonsense mutations by amlexanox in human cells.

Authors:  Sara Gonzalez-Hilarion; Terence Beghyn; Jieshuang Jia; Nadège Debreuck; Gonzague Berte; Kamel Mamchaoui; Vincent Mouly; Dieter C Gruenert; Benoit Déprez; Fabrice Lejeune
Journal:  Orphanet J Rare Dis       Date:  2012-08-31       Impact factor: 4.123

3.  Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation.

Authors:  Malka Nissim-Rafinia; Micha Aviram; Scott H Randell; Liat Shushi; Efrat Ozeri; Ornit Chiba-Falek; Ofer Eidelman; Harvey B Pollard; James R Yankaskas; Batsheva Kerem
Journal:  EMBO Rep       Date:  2004-11       Impact factor: 8.807

4.  Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Authors:  Steven Molinski; Paul D W Eckford; Stan Pasyk; Saumel Ahmadi; Stephanie Chin; Christine E Bear
Journal:  Front Pharmacol       Date:  2012-09-26       Impact factor: 5.810

5.  Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.

Authors:  Daniela De Stefano; Valeria R Villella; Speranza Esposito; Antonella Tosco; Angela Sepe; Fabiola De Gregorio; Laura Salvadori; Rosa Grassia; Carlo A Leone; Giuseppe De Rosa; Maria C Maiuri; Massimo Pettoello-Mantovani; Stefano Guido; Anna Bossi; Anna Zolin; Andrea Venerando; Lorenzo A Pinna; Anil Mehta; Gianni Bona; Guido Kroemer; Luigi Maiuri; Valeria Raia
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

6.  Assessment of p.Phe508del-CFTR functional restoration in pediatric primary cystic fibrosis airway epithelial cells.

Authors:  Erika N Sutanto; Amelia Scaffidi; Luke W Garratt; Kevin Looi; Clara J Foo; Michela A Tessari; Richard A Janssen; David F Fischer; Stephen M Stick; Anthony Kicic
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

7.  Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases.

Authors:  Hana Benhabiles; Sara Gonzalez-Hilarion; Séverine Amand; Christine Bailly; Anne Prévotat; Philippe Reix; Dominique Hubert; Eric Adriaenssens; Sylvie Rebuffat; David Tulasne; Fabrice Lejeune
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

8.  Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue.

Authors:  Steven V Molinski; Saumel Ahmadi; Wan Ip; Hong Ouyang; Adriana Villella; John P Miller; Po-Shun Lee; Kethika Kulleperuma; Kai Du; Michelle Di Paola; Paul Dw Eckford; Onofrio Laselva; Ling Jun Huan; Leigh Wellhauser; Ellen Li; Peter N Ray; Régis Pomès; Theo J Moraes; Tanja Gonska; Felix Ratjen; Christine E Bear
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137

9.  Genetically encoded optical sensors for monitoring of intracellular chloride and chloride-selective channel activity.

Authors:  Piotr Bregestovski; Tatyana Waseem; Marat Mukhtarov
Journal:  Front Mol Neurosci       Date:  2009-12-04       Impact factor: 5.639

10.  A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

Authors:  A Tosco; F De Gregorio; S Esposito; D De Stefano; I Sana; E Ferrari; A Sepe; L Salvadori; P Buonpensiero; A Di Pasqua; R Grassia; C A Leone; S Guido; G De Rosa; S Lusa; G Bona; G Stoll; M C Maiuri; A Mehta; G Kroemer; L Maiuri; V Raia
Journal:  Cell Death Differ       Date:  2016-04-01       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.